Search
News & Events
Bupa pledges half a million dollars to end rheumatic heart diseaseResearchers will extend a unique community-led project to end rheumatic heart disease in Aboriginal communities, thanks to nearly half a million dollars in funding from Bupa.
Research
Public health and economic perspectives on acute rheumatic fever and rheumatic heart diseaseEfforts to eliminate ARF and RHD in Australia over the past decade have so far been unsuccessful, but this can change
Research
Severe adverse events following benzathine penicillin G injection for rheumatic heart disease prophylaxis: cardiac compromise more likely than anaphylaxisThese results indicate that anaphylaxis is not a major cause of adverse reactions to benzathine penicillin G
Research
Voices behind the statistics: A systematic literature review of the lived experience of rheumatic heart diseaseThis systematic review presents a critical, interpretive analysis of publications that include lived experiences of rheumatic heart disease
Research
How many doses make a difference? An analysis of secondary prevention of rheumatic fever and rheumatic heart diseaseincreased adherence to penicillin prophylaxis is associated with reduced acute rheumatic fever recurrence and a likely reduction in mortality
News & Events
Carol's story: losing a parent to RHDAfter being diagnosed with rheumatic heart disease at ten, Elizabeth had to leave country and her family for a large chunk of her childhood so she could be treated in Adelaide.
Research
Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical ConsiderationsA directed approach to the differential diagnosis of acute rheumatic fever now includes the concept of low-risk versus medium-to-high risk populations
News & Events
Major grants fuel child health researchSix researchers from The Kids Research Institute Australia have been awarded $8.9 million in prestigious Investigator Grants from the National Health and Medical Research Council.
Research
Time to address the neglected burden of group A StreptococcusJonathan Jeffrey Carapetis AM Cannon AM MBBS FRACP FAFPHM PhD FAHMS BSc(Hons) BBus PhD Executive Director; Co-Head, Strep A Translation; Co-Founder
Research
Global epidemiology of valvular heart diseaseValvular heart disease is a major contributor to loss of physical function, quality of life and longevity. The epidemiology of VHD varies substantially around the world, with a predominance of functional and degenerative disease in high-income countries, and a predominance of rheumatic heart disease in low-income and middle-income countries. Reflecting this distribution, rheumatic heart disease remains by far the most common manifestation of VHD worldwide and affects approximately 41 million people.